DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers

Journal of Clinical Oncology

Volumn 18, Issue 21 SUPPL., 2000, Pages

  Markowitz, S ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRANSFORMING GROWTH FACTOR BETA;

BASE MISPAIRING; COLON CARCINOGENESIS; COLON CARCINOMA; DNA REPAIR; FAMILIAL CANCER; GENE INACTIVATION; HUMAN; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BASE PAIR MISMATCH; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS;

EID: 0034329427     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Mismatch repair defects in human carcinogenesis
2. Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspective
3. Mismatch repair, genetic stability, and cancer
4. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
5. Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer
6. Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair
7. Frameshift mutator mutations
8. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells
9. Isolation of an hMSH2-p 160 heterodimer that restores DNA mismatch repair to tumor cells
10. Mutations of a mutL homolog in hereditary colon cancer
11. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
12. Mutations in two PMS homologues in hereditary nonpolyposis colon cancer
13. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs
14. Heredity with reference to carcinoma
15. Hereditary nonpolyposis colorectal cancer (Lynch Syndromes I and II): Genetics, pathology, natural history and cancer control, Part I
16. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)
17. Genetic instability associated with adenoma to carcinoma progression in hereditary nonpolyposis colon cancer
18. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer
19. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients
20. Aggressive polyps in hereditary nonpolyposis colorectal cancer: Targets for screening
21. The tumor spectrum in hereditary non-polyposis colorectal cancer: A study of 24 kindreds in the Netherlands
22. Microsatellite instability in Muir-Torre syndrome
23. hMSH2 mutations in hereditary non-polyposis colorectal cancer kindreds
24. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
25. + tumor cells
26. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability
27. Mismatch repair deficiency in phenotypically normal human cells
28. Clues to the pathogenesis of familial colorectal cancer
29. Microsatellite instability in cancer of the proximal colon
30. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
31. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
32. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
33. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
34. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
35. Genetic instability occurs in the majority of young patients with colorectal cancer
36. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer
37. Mutator phenotypes in human colorectal carcinoma cell lines
38. Mutator phenotype may be required for multistage carcinogenesis
39. APC mutations in colorectal tumors with mismatch repair deficiency
40. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer
41. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene
42. Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line
43. Tumor suppressor activity of the TGF-β pathway in human cancers
44. The transforming growth factor-betas
45. The transforming growth factor beta family
46. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights
47. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor beta during tumor progression
48. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector
49. Repression of autocrine transforming growth factor beta-1 and beta-2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties
50. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta-1
51. Genetic changes in the transforming growth factor beta (TGF-β) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-β
52. Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines
53. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF β): Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β
54. Expression cloning of the TGF-β type II receptor a functional transmembrane serine/threonine kinase
55. TGFβ signals through a heteromeric protein kinase receptor complex
56. The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand
57. Mechanism of activation of the TGF-β receptor
58. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
59. Microsatellite instability and mutations of the TGF-β type II receptor gene in colorectal cancer
60. Demonstration that mutation of the type II TGF-β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
61. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
62. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas
63. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
64. Madr2 maps to 18q21 and encodes a TGF-β regulated Mad-related protein that is functionally mutated in colorectal carcinoma
65. Evaluation of candidate tumour suppressor genes on chromosome 18q loss in colorectal cancers
66. MAD-related genes in the human
67. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history
68. Better survival rates in patients with Mlh1-associated hereditary colon cancer
69. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH 1 mutation
70. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not 1,3 bis(2-chloroethyl)nitrosourea
71. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint
72. 4-methylthymine, or the cisplatin-d(GpG) adduct
73. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine